Protein kinase G positively regulates proteasome-mediated degradation of misfolded proteins

Mark J. Ranek, Erin J M Terpstra, Jie Li, David A. Kass, Xuejun Wang

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background-Proteasome functional insufficiency is implicated in a large subset of cardiovascular diseases and may play an important role in their pathogenesis. The regulation of proteasome function is poorly understood, hindering the development of effective strategies to improve proteasome function. Methods and Results- Protein kinase G (PKG) was manipulated genetically and pharmacologically in cultured cardiomyocytes. Activation of PKG increased proteasome peptidase activities, facilitated proteasome-mediated degradation of surrogate (enhanced green fluorescence protein modified by carboxyl fusion of degron CL1) and bona fide (CryAB) misfolded proteins, and attenuated CryAB overexpression-induced accumulation of ubiquitinated proteins and cellular injury. PKG inhibition elicited the opposite responses. Differences in the abundance of the key 26S proteasome subunits Rpt6 and β5 between the PKG-manipulated and control groups were not statistically significant, but the isoelectric points were shifted by PKG activation. In transgenic mice expressing a surrogate substrate (GFPdgn), PKG activation by sildenafil increased myocardial proteasome activities and significantly decreased myocardial GFPdgn protein levels. Sildenafil treatment significantly increased myocardial PKG activity and significantly reduced myocardial accumulation of CryAB, ubiquitin conjugates, and aberrant protein aggregates in mice with CryAB-based desmin-related cardiomyopathy. No discernible effect on bona fide native substrates of the ubiquitin-proteasome system was observed from PKG manipulation in vitro or in vivo. Conclusions-PKG positively regulates proteasome activities and proteasome-mediated degradation of misfolded proteins, likely through posttranslational modifications to proteasome subunits. This may be a new mechanism underlying the benefit of PKG stimulation in treating cardiac diseases. Stimulation of PKG by measures such as sildenafil administration is potentially a new therapeutic strategy to treat cardiac proteinopathies.

Original languageEnglish (US)
Pages (from-to)365-376
Number of pages12
JournalCirculation
Volume128
Issue number4
DOIs
StatePublished - Jul 23 2013

Fingerprint

Cyclic GMP-Dependent Protein Kinases
Proteasome Endopeptidase Complex
Proteolysis
Ubiquitin
Ubiquitinated Proteins
Proteins
Desmin
Isoelectric Point
Post Translational Protein Processing
Cardiomyopathies
Cardiac Myocytes
Transgenic Mice
Heart Diseases
Peptide Hydrolases
Cardiovascular Diseases
Fluorescence

Keywords

  • cardiomyopathies
  • cyclic GMP-dependent protein kinase
  • desmin
  • proteasome inhibitors
  • proteins

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Protein kinase G positively regulates proteasome-mediated degradation of misfolded proteins. / Ranek, Mark J.; Terpstra, Erin J M; Li, Jie; Kass, David A.; Wang, Xuejun.

In: Circulation, Vol. 128, No. 4, 23.07.2013, p. 365-376.

Research output: Contribution to journalArticle

Ranek, Mark J. ; Terpstra, Erin J M ; Li, Jie ; Kass, David A. ; Wang, Xuejun. / Protein kinase G positively regulates proteasome-mediated degradation of misfolded proteins. In: Circulation. 2013 ; Vol. 128, No. 4. pp. 365-376.
@article{42d39d2fd2254438a10ef4d5e0394181,
title = "Protein kinase G positively regulates proteasome-mediated degradation of misfolded proteins",
abstract = "Background-Proteasome functional insufficiency is implicated in a large subset of cardiovascular diseases and may play an important role in their pathogenesis. The regulation of proteasome function is poorly understood, hindering the development of effective strategies to improve proteasome function. Methods and Results- Protein kinase G (PKG) was manipulated genetically and pharmacologically in cultured cardiomyocytes. Activation of PKG increased proteasome peptidase activities, facilitated proteasome-mediated degradation of surrogate (enhanced green fluorescence protein modified by carboxyl fusion of degron CL1) and bona fide (CryAB) misfolded proteins, and attenuated CryAB overexpression-induced accumulation of ubiquitinated proteins and cellular injury. PKG inhibition elicited the opposite responses. Differences in the abundance of the key 26S proteasome subunits Rpt6 and β5 between the PKG-manipulated and control groups were not statistically significant, but the isoelectric points were shifted by PKG activation. In transgenic mice expressing a surrogate substrate (GFPdgn), PKG activation by sildenafil increased myocardial proteasome activities and significantly decreased myocardial GFPdgn protein levels. Sildenafil treatment significantly increased myocardial PKG activity and significantly reduced myocardial accumulation of CryAB, ubiquitin conjugates, and aberrant protein aggregates in mice with CryAB-based desmin-related cardiomyopathy. No discernible effect on bona fide native substrates of the ubiquitin-proteasome system was observed from PKG manipulation in vitro or in vivo. Conclusions-PKG positively regulates proteasome activities and proteasome-mediated degradation of misfolded proteins, likely through posttranslational modifications to proteasome subunits. This may be a new mechanism underlying the benefit of PKG stimulation in treating cardiac diseases. Stimulation of PKG by measures such as sildenafil administration is potentially a new therapeutic strategy to treat cardiac proteinopathies.",
keywords = "cardiomyopathies, cyclic GMP-dependent protein kinase, desmin, proteasome inhibitors, proteins",
author = "Ranek, {Mark J.} and Terpstra, {Erin J M} and Jie Li and Kass, {David A.} and Xuejun Wang",
year = "2013",
month = "7",
day = "23",
doi = "10.1161/CIRCULATIONAHA.113.001971",
language = "English (US)",
volume = "128",
pages = "365--376",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Protein kinase G positively regulates proteasome-mediated degradation of misfolded proteins

AU - Ranek, Mark J.

AU - Terpstra, Erin J M

AU - Li, Jie

AU - Kass, David A.

AU - Wang, Xuejun

PY - 2013/7/23

Y1 - 2013/7/23

N2 - Background-Proteasome functional insufficiency is implicated in a large subset of cardiovascular diseases and may play an important role in their pathogenesis. The regulation of proteasome function is poorly understood, hindering the development of effective strategies to improve proteasome function. Methods and Results- Protein kinase G (PKG) was manipulated genetically and pharmacologically in cultured cardiomyocytes. Activation of PKG increased proteasome peptidase activities, facilitated proteasome-mediated degradation of surrogate (enhanced green fluorescence protein modified by carboxyl fusion of degron CL1) and bona fide (CryAB) misfolded proteins, and attenuated CryAB overexpression-induced accumulation of ubiquitinated proteins and cellular injury. PKG inhibition elicited the opposite responses. Differences in the abundance of the key 26S proteasome subunits Rpt6 and β5 between the PKG-manipulated and control groups were not statistically significant, but the isoelectric points were shifted by PKG activation. In transgenic mice expressing a surrogate substrate (GFPdgn), PKG activation by sildenafil increased myocardial proteasome activities and significantly decreased myocardial GFPdgn protein levels. Sildenafil treatment significantly increased myocardial PKG activity and significantly reduced myocardial accumulation of CryAB, ubiquitin conjugates, and aberrant protein aggregates in mice with CryAB-based desmin-related cardiomyopathy. No discernible effect on bona fide native substrates of the ubiquitin-proteasome system was observed from PKG manipulation in vitro or in vivo. Conclusions-PKG positively regulates proteasome activities and proteasome-mediated degradation of misfolded proteins, likely through posttranslational modifications to proteasome subunits. This may be a new mechanism underlying the benefit of PKG stimulation in treating cardiac diseases. Stimulation of PKG by measures such as sildenafil administration is potentially a new therapeutic strategy to treat cardiac proteinopathies.

AB - Background-Proteasome functional insufficiency is implicated in a large subset of cardiovascular diseases and may play an important role in their pathogenesis. The regulation of proteasome function is poorly understood, hindering the development of effective strategies to improve proteasome function. Methods and Results- Protein kinase G (PKG) was manipulated genetically and pharmacologically in cultured cardiomyocytes. Activation of PKG increased proteasome peptidase activities, facilitated proteasome-mediated degradation of surrogate (enhanced green fluorescence protein modified by carboxyl fusion of degron CL1) and bona fide (CryAB) misfolded proteins, and attenuated CryAB overexpression-induced accumulation of ubiquitinated proteins and cellular injury. PKG inhibition elicited the opposite responses. Differences in the abundance of the key 26S proteasome subunits Rpt6 and β5 between the PKG-manipulated and control groups were not statistically significant, but the isoelectric points were shifted by PKG activation. In transgenic mice expressing a surrogate substrate (GFPdgn), PKG activation by sildenafil increased myocardial proteasome activities and significantly decreased myocardial GFPdgn protein levels. Sildenafil treatment significantly increased myocardial PKG activity and significantly reduced myocardial accumulation of CryAB, ubiquitin conjugates, and aberrant protein aggregates in mice with CryAB-based desmin-related cardiomyopathy. No discernible effect on bona fide native substrates of the ubiquitin-proteasome system was observed from PKG manipulation in vitro or in vivo. Conclusions-PKG positively regulates proteasome activities and proteasome-mediated degradation of misfolded proteins, likely through posttranslational modifications to proteasome subunits. This may be a new mechanism underlying the benefit of PKG stimulation in treating cardiac diseases. Stimulation of PKG by measures such as sildenafil administration is potentially a new therapeutic strategy to treat cardiac proteinopathies.

KW - cardiomyopathies

KW - cyclic GMP-dependent protein kinase

KW - desmin

KW - proteasome inhibitors

KW - proteins

UR - http://www.scopus.com/inward/record.url?scp=84880724298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880724298&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.113.001971

DO - 10.1161/CIRCULATIONAHA.113.001971

M3 - Article

VL - 128

SP - 365

EP - 376

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -